| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-03-11 | Bleichroeder LP | Cue Biopharma, Inc. | 2,755,028 | 6.1% | EDGAR |
| SC 13G | 2024-02-07 | BlackRock Inc. | Cue Biopharma, Inc. | 2,247,978 | 5.0% | EDGAR |
| SC 13G | 2024-01-31 | BlackRock Inc. | Cue Biopharma, Inc. | 2,338,765 | 5.2% | EDGAR |
| SC 13G | 2023-02-14 | Slate Path Capital LP | Cue Biopharma, Inc. | 2,402,455 | 5.6% | EDGAR |
| SC 13G/A | 2023-02-03 | STATE STREET CORP | Cue Biopharma, Inc. | - | 0.3% | EDGAR |
| SC 13G/A | 2022-12-02 | Nantahala Capital Management, LLC | Cue Biopharma, Inc. | 93,297 | 0.3% | EDGAR |
| SC 13G | 2022-11-18 | Slate Path Capital LP | Cue Biopharma, Inc. | 2,402,455 | 5.6% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Cue Biopharma, Inc. | 831,925 | 2.4% | EDGAR |
| SC 13G/A | 2022-02-14 | Nantahala Capital Management, LLC | Cue Biopharma, Inc. | 2,539,700 | 8.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Corriente Advisors, LLC | Cue Biopharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2022-02-10 | STATE STREET CORP | Cue Biopharma, Inc. | - | 5.2% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | Cue Biopharma, Inc. | 2,290,269 | 7.2% | EDGAR |
| SC 13G | 2021-02-16 | Corriente Advisors, LLC | Cue Biopharma, Inc. | 1,915,219 | 6.3% | EDGAR |
| SC 13G/A | 2021-02-12 | Avoro Capital Advisors LLC | Cue Biopharma, Inc. | 452,500 | 1.5% | EDGAR |
| SC 13G/A | 2021-02-12 | Nantahala Capital Management, LLC | Cue Biopharma, Inc. | 2,506,772 | 8.3% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | Cue Biopharma, Inc. | 2,162,978 | 7.1% | EDGAR |
| SC 13D/A | 2020-04-21 | MARLETT CHRISTOPHER A | Cue Biopharma, Inc. | 1,357,821 | 4.9% | EDGAR |
| SC 13G | 2020-02-14 | Avoro Capital Advisors LLC | Cue Biopharma, Inc. | 1,870,000 | 8.1% | EDGAR |
| SC 13G | 2020-02-14 | Nantahala Capital Management, LLC | Cue Biopharma, Inc. | 1,404,941 | 6.1% | EDGAR |
| SC 13G | 2020-02-07 | BlackRock Inc. | Cue Biopharma, Inc. | 1,387,669 | 6.0% | EDGAR |